One case, two opinions.
Toyota Motor Sales, U.S.A., Inc. v. Allen Interchange LLC, 2023
WL 5206884, No. 22-cv-1681 (KMM/JFD) (D. Minn. Aug. 14, 2023)
This opinion deals only with Allen’s counterclaims. Allen
distributes Toyota replacement parts, manufactured by authorized suppliers
around the world. According to Allen,
Toyota USA “sells Toyota Parts in the United States at prices substantially
higher than those charged by Toyota in other places.” The Toyota parts sold by
Allen Interchange and Toyota bear the same part number, and according to Allen
Interchange, are identical in design, function, and quality. Toyota USA sued
Allen for grey marketing in violation of the Lanham Act and related claims,
asserting that material differences included the existence of a
manufacturer-backed warranty, the shipping and packaging of the parts, and the
appearance and condition of the parts.
Allen counterclaimed for antitrust and related unfair
competition/tortious interference claims. The court declined to dismiss the
counterclaims.
Lanham Act false advertising: Allen alleged that Toyota’s
statements that “[t]he purchase ... of unauthorized, gray market parts within [Toyota
USA’s] PMA [Primary Market Area], or anywhere, is ... a breach of your dealer
agreement” constituted false advertising because the agreement in fact allows
for purchases of Toyota parts from other sources, including for non-warranty repairs.
The counterclaim also alleged false/misleading use of the term “Genuine Toyota
Parts”; statements about safety of “gray market parts” even though they are
made by Toyota entities; and misleading assertions about Allen Interchange’s
products in flyers depicting a pallet with Toyota parts recognizable as an
Allen Interchange shipment.
Toyota argued that its statements were literally true, but literally true claims can mislead—a classic question of fact. Plus, statements about commercial activities are actionable and Allen adequately alleged falsity.
Toyota Motor Sales, U.S.A., Inc. v. Allen Interchange LLC,
2023 WL 5207389, No. 22-cv-1681 (KMM/JFD) (D. Minn. Aug. 14, 2023)
This is the trademark side of the case. The court denied
Allen’s motion for joinder of Toyota Japan and allowed key claims to proceed.
This case is one of several that makes me think that a
coherent version of trademark could emerge from cases like Abitron and Lexmark:
registered trademarks get special treatment, even including (though I think
it’s a bad idea) not having a harm requirement as an element of the cause of
action, whereas unregistered/§43(a) claims need to show harm. This isn’t
directly implicated by the case, but the reasons we might have different
treatment are.
In particular, Toyota USA doesn’t own the Toyota marks; it
is a licensee. This was a matter of statutory standing, not Article III
standing.
First, the dilution claims require an “owner” of a famous
mark to bring suit. Thus, they were dismissed. While some cases have allowed an
exclusive licensee to do bring a dilution claim, Toyota USA didn’t plead that it was the exclusive
licensee and acknowledged in its briefing that it wasn’t. Being an exclusive
authorized importer and distributor was not enough, because an “exclusive
licensee” is the sole entity with an interest in a trademark, while an
“exclusive importer and distributor” could be one of multiple entities with
such an interest.
Anyway, even if Toyota USA could be considered an exclusive
licensee, the relevant cases covered only §43(a)(1)(A), not §43(c), which explicitly
uses the term “owner” when identifying who may bring suit, whereas § 43(a) uses
the broader language of “any person.” Minnesota’s trademark statute also said that
“[t]he owner of a mark that is famous in this state may” seek an injunction in
the event of trademark dilution. Likewise, “[o]nly the owner of the trademark
has standing to seek relief for common law trademark infringement.”
Allen is definitely not out of the woods, because
§43(a)(1)(A) is still available, but that should matter to the burden Toyota
USA faces, including the Court’s language in Lexmark about proof of
harm, which is not limited to false advertising.
No comments:
Post a Comment